1. Home
  2. GLPG vs CYD Comparison

GLPG vs CYD Comparison

Compare GLPG & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.75

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

HOLD

Current Price

$47.43

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
CYD
Founded
1999
1951
Country
Belgium
Singapore
Employees
452
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.6B
IPO Year
N/A
1998

Fundamental Metrics

Financial Performance
Metric
GLPG
CYD
Price
$27.75
$47.43
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$36.50
$60.00
AVG Volume (30 Days)
129.6K
98.9K
Earning Date
05-06-2026
02-24-2026
Dividend Yield
N/A
1.32%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.11
Revenue Next Year
N/A
$8.67
P/E Ratio
N/A
$32.71
Revenue Growth
N/A
N/A
52 Week Low
$25.97
$16.77
52 Week High
$37.78
$56.55

Technical Indicators

Market Signals
Indicator
GLPG
CYD
Relative Strength Index (RSI) 36.53 67.27
Support Level N/A $35.24
Resistance Level $34.04 $56.55
Average True Range (ATR) 0.56 2.02
MACD 0.08 0.64
Stochastic Oscillator 25.33 97.72

Price Performance

Historical Comparison
GLPG
CYD

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: